Literature DB >> 27613818

Role of the PI3K-Akt Signaling Pathway in the Pathogenesis of Polycystic Ovary Syndrome.

Tiantian Li1, Hui Mo2, Wenfeng Chen1, Li Li1,2, Yao Xiao2, Jing Zhang3, Xiaofang Li1, Ying Lu1.   

Abstract

This review aimed to focus on the recent progress of the understanding of the role of phosphatidylinositol 3-kinase (PI3K) in polycystic ovary syndrome (PCOS). In recent years, it has been increasingly recognized that PI3K plays an important role in PCOS whose pathogenesis is unclear. However, research continues into revealing the details of how PI3Ks are involved in developing PCOS. Previous studies have shown that activation of the PI3K-protein kinase B (Akt) signaling pathway has important effects on insulin resistance and endometrial cancer. Knowledge of the action of PI3K in PCOS might provide valuable information to further validate the pathogenesis of PCOS and suggest new methods of treatment.

Entities:  

Keywords:  PI3K-Akt; insulin resistance; pathogenesis; polycystic ovary syndrome; signaling pathway

Mesh:

Substances:

Year:  2016        PMID: 27613818     DOI: 10.1177/1933719116667606

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  29 in total

1.  Heat therapy improves glucose tolerance and adipose tissue insulin signaling in polycystic ovary syndrome.

Authors:  Brett R Ely; Zachary S Clayton; Carrie E McCurdy; Joshua Pfeiffer; Karen Wiedenfeld Needham; Lindan N Comrada; Christopher T Minson
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-05-28       Impact factor: 4.310

2.  Metformin and sitagliptin combination therapy ameliorates polycystic ovary syndrome with insulin resistance through upregulation of lncRNA H19.

Authors:  Qiong Wang; Jing Shang; Yun Zhang; Wei Zhou
Journal:  Cell Cycle       Date:  2019-08-12       Impact factor: 4.534

3.  Protective effects of lidocaine on polycystic ovary syndrome through modulating ovarian granulosa cell physiology via PI3K/AKT/mTOR pathway.

Authors:  Haixia Xiong; Qiong Hu; Qun Jiang
Journal:  Cytotechnology       Date:  2022-02-24       Impact factor: 2.058

4.  The Upregulation of HAS2-AS1 Relates to the Granulosa Cell Dysfunction by Repressing TGF-β Signaling and Upregulating HAS2.

Authors:  Yungai Xiang; Guo Yu; Yuxia Song; Yan Li; Lanlan Cheng; Pengfen Li; Le Zhang; Meng Wang; Li Tan
Journal:  Mol Cell Biol       Date:  2022-08-08       Impact factor: 5.069

Review 5.  Trends in insulin resistance: insights into mechanisms and therapeutic strategy.

Authors:  Mengwei Li; Xiaowei Chi; Ying Wang; Sarra Setrerrahmane; Wenwei Xie; Hanmei Xu
Journal:  Signal Transduct Target Ther       Date:  2022-07-06

6.  Developmental Programming: Prenatal Testosterone Excess on Ovarian SF1/DAX1/FOXO3.

Authors:  Muraly Puttabyatappa; Valentina Matiller; Antonela F Stassi; Natalia R Salvetti; Hugo H Ortega; Vasantha Padmanabhan
Journal:  Reprod Sci       Date:  2020-01-01       Impact factor: 3.060

7.  Protective effects of berberine in a rat model of polycystic ovary syndrome mediated via the PI3K/AKT pathway.

Authors:  Jia Yu; Caifei Ding; Zhoujia Hua; Xuejuan Jiang; Chenye Wang
Journal:  J Obstet Gynaecol Res       Date:  2021-03-11       Impact factor: 1.730

8.  MiR-379-5p Promotes Chondrocyte Proliferation via Inhibition of PI3K/Akt Pathway by Targeting YBX1 in Osteoarthritis.

Authors:  Hongjun Zhang; Wendi Zheng; Du Li; Jia Zheng
Journal:  Cartilage       Date:  2022 Jan-Mar       Impact factor: 3.117

9.  Single-cell analysis of differences in transcriptomic profiles of oocytes and cumulus cells at GV, MI, MII stages from PCOS patients.

Authors:  Qiwei Liu; Yumei Li; Yun Feng; Chaojie Liu; Jieliang Ma; Yifei Li; Huifen Xiang; Yazhong Ji; Yunxia Cao; Xiaowen Tong; Zhigang Xue
Journal:  Sci Rep       Date:  2016-12-22       Impact factor: 4.379

10.  Defective insulin signaling and the protective effects of dimethyldiguanide during follicular development in the ovaries of polycystic ovary syndrome.

Authors:  Fan Wang; Shaobing Wang; Zhenghong Zhang; Qingqiang Lin; Yiping Liu; Yijun Xiao; Kaizhuan Xiao; Zhengchao Wang
Journal:  Mol Med Rep       Date:  2017-09-29       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.